샘플 요청 목록

 카트 문의
시장보고서
상품코드
2143639

편두통 치료제 시장

Migraine Drugs
발행일: | 리서치사: 구분자 Market Glass, Inc. | 페이지 정보: 영문 500 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 7,914,000
PDF & Excel (Team License: Up to 10 users) help
PDF & Excel 보고서를 동일 기업 내 최대 10명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기가 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 이용자 1명당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 11,115 금액 안내 화살표 ￦ 15,037,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 23,743,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 편두통 치료제 시장은 2032년까지 147억 달러에 이를 전망

2025년에 73억 달러로 평가된 세계의 편두통 치료제 시장은 2025년부터 2032년 분석 기간 동안 CAGR 10.4%로 성장하여 2032년까지 147억 달러에 이를 것으로 예상되고 있습니다. 본 보고서로 분석 대상이 되고 있는 부문 중 하나인 ' 급성기 치료 '는 CAGR 8.9%를 나타내고, 분석 기간 종료까지 84억 달러에 이를 것으로 예상되고 있습니다.' 예방 치료 ' 부문의 성장률은 분석 기간을 통해서 CAGR 12.9%로 추정되고 있습니다.

미국 시장은 20억 달러로 평가되는 한편, 중국은 CAGR 13.5%를 나타낼 것으로 예측됩니다.

2025년 미국의 편두통 치료제 시장 규모는 20억 달러로 평가되었습니다. 세계 제 2위 경제 규모를 자랑하는 중국에 대해는 2025년부터 2032년 분석 기간 동안 CAGR 13.5%로 성장을 지속하여, 2032년까지 시장 규모가 30억 달러에 이를 것으로 예측됩니다. 기타 주목해야 할 지역 시장으로서는 일본과 캐나다를 들 수 있어 분석 기간 중에 각각 CAGR 8.0% 및 9.4%를 나타낼 것으로 예측됩니다. 유럽내에서는 독일이 CAGR 약 8.3%를 나타낼 것으로 예측됩니다.

세계의 편두통 치료제 시장 - 주요 동향 및 성장 촉진요인 개요

편두통 치료제는 격렬하고 반복적인 두통을 특징으로 하며, 종종 메스꺼움, 구토, 빛이나 소리에 대한 과민성을 동반하여 일상생활에 지장을 주는 신경 질환인 편두통의 관리 및 치료에 있어 매우 중요합니다. 이러한 약물은 편두통 발작 중 증상을 완화하는 ‘급성기 치료제’와 발작의 빈도나 중증도를 경감시키는 ‘예방 치료제’로 크게 구분됩니다. 급성기 치료제에는 트립탄 계열 약물, 에르고타민 계열 약물, 비스테로이드성 항염증제(NSAIDs)가 포함되며, 예방 치료제에는 β-차단제, 항경련제, 그리고 새로운 계열의 칼시토닌 유전자 관련 펩티드(CGRP) 억제제가 포함됩니다. 엘렌마브, 프레마네즈마브, 갈카네즈마브 등의 CGRP 억제제는 편두통의 병태생리에서 중요한 역할을 하는 CGRP 경로를 표적으로 삼음으로써 편두통 예방에 혁명을 일으켰습니다. 이러한 표적 치료법이 이용 가능해짐에 따라, 기존 약물로 충분한 증상 완화를 얻지 못했던 많은 편두통 환자의 삶의 질이 크게 개선되었습니다.

편두통 유병률 증가와 이 질환이 삶의 질에 미치는 영향에 대한 인식이 높아지는 것을 배경으로, 편두통 치료제 세계 시장은 급속히 확대되고 있습니다. 세계보건기구(WHO)에 따르면, 편두통은 전 세계적으로 주요 장애 원인 중 하나이며, 약 10억 명이 앓고 있는 것으로 추정됩니다. 이러한 높은 유병률은 효과적인 편두통 관리 전략의 필요성을 부각시키며, 이 분야의 연구 개발을 촉진하고 있습니다. 제약사들은 효능 향상과 부작용 감소를 실현하는 차세대 CGRP 억제제나 병용 요법 등 새로운 편두통 치료법 개발에 막대한 투자를 하고 있습니다. 또한, 모바일 앱과 웨어러블 기기를 활용하여 편두통을 모니터링하고 관리하는 디지털 테라퓨틱스의 도입은 개인 맞춤형 편두통 관리에 있어 큰 진전이라고 할 수 있습니다. 이러한 디지털 도구를 통해 환자는 자신의 증상, 유발 요인, 복약 상황을 추적할 수 있게 되어, 보다 정확하고 효과적인 치료 계획을 수립할 수 있게 됩니다.

편두통 치료제 시장의 성장은 의약품 개발 분야의 기술적 진보, 맞춤형 의료에 대한 수요 증가, 만성 편두통 유병률 상승 등 여러 요인에 의해 주도되고 있습니다. 기술 혁신을 통해 CGRP 억제제 등 더 효과적이고 표적화된 치료법이 개발되어 편두통 예방과 치료에 혁신을 가져왔습니다. 환자들이 자신의 특정 유전적 요인이나 생활 습관에 맞춘 치료를 요구하게 됨에 따라, 맞춤형 의료에 대한 수요 증가도 시장을 뒷받침하고 있습니다. 또한, 전 세계 인구의 상당 부분에 영향을 미치는 만성 편두통 유병률의 상승으로 인해 효과적인 편두통 치료법에 대한 큰 수요가 발생하고 있습니다. 신흥 시장의 의료 인프라 확충과 첨단 편두통 치료에 대한 접근성 향상도 시장 성장을 더욱 뒷받침하고 있습니다. 또한, 편두통과 그 치료법에 대한 인식과 지식이 향상됨에 따라 환자들이 적극적으로 의료 도움을 구하게 되었고, 그 결과 편두통 치료제에 대한 수요가 촉진되고 있습니다. 이러한 요인들이 복합적으로 작용하여 편두통 치료제 시장의 견실한 성장에 기여하고 있으며, 이는 의학 연구의 지속적인 발전과 전 세계 편두통 환자들의 변화하는 요구를 반영한 것입니다.

부문 :

치료법(급성 치료, 예방 치료), 치료제 분류(CGRP 단일클론항체, CGRP저분자 길항제, 아세틸콜린 억제제/신경 독소, 트리프탄계, 디 탄계, 맥각 알카로이드, NSAIDs, 기타), 투여 경로(경구투여, 주사 투여, 기타 투여 경로), 연령층(소아, 성인, 고령자)

주요 기업

  • Allergan PLC
  • Amgen, Inc.
  • Biohaven Pharmaceutical Holding Company Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson &Johnson
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.

각 분야의 전문가들의 견해를 바탕으로 합니다. 산업계, 기업, 학계에 걸친 각 분야의 전문가들로부터 얻은 견해를 반영하여, 기존에 발표된 조사 결과 이상의 맥락을 더하고 있습니다.

시장의 초기 신호를 포착합니다. - 기존의 2차 조사에 완전히 반영되기 전에, 전문가 간의 대화, 기업의 동향, 시장과 관련된 논의를 통해 드러나는 변화를 추적합니다.

광범위하고 검증된 정보 기반을 활용합니다. - 컨퍼런스 세션, 기조 연설, 패널 토론, 블로그, 기업의 공시 정보, 연차 보고서, 기관 간행물 및 기타 검증된 정보 출처에서 얻은 인사이트를 통합하고 있습니다.

신호와 전략적 시장 방향성을 연결합니다. - 이러한 관점을 통합하여 시장이 어디로 향하고 있는지, 그 움직임을 주도하는 요인은 무엇인지, 그리고 전략에 있어 가장 중요할 가능성이 있는 동향은 무엇인지 파악합니다.

상세한 기업 정보를 제공합니다 - 시장 수준의 분석에 그치지 않고, 경쟁 환경에 참여하며 그 형성에 기여하고 있는 기업을 상세하게 검증합니다.

주요 지역 시장 점유율을 면밀히 검토합니다. - 단일 세계 시장 점유율 수치만으로는 전체적인 상황을 파악하기 어렵습니다. 경쟁 구도는 지역에 따라 크게 다를 수 있습니다. 분석상 관련성이 있는 경우, Market Glass의 보고서는 각 시장의 구조와 동향에 맞추어 상세도를 조정하여 주요 지역 시장 점유율 분석을 심층적으로 다룹니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향 및 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KTH 26.10.14

Global Migraine Drugs Market to Reach US$14.7 Billion by 2032

The global market for Migraine Drugs estimated at US$7.3 Billion in the year 2025, is expected to reach US$14.7 Billion by 2032, growing at a CAGR of 10.4% over the analysis period 2025-2032. Acute Treatment, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$8.4 Billion by the end of the analysis period. Growth in the Preventive Treatment segment is estimated at 12.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 13.5% CAGR

The Migraine Drugs market in the U.S. is estimated at US$2.0 Billion in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$3.0 Billion by the year 2032 trailing a CAGR of 13.5% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 9.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global Migraine Drugs Market - Key Trends and Drivers Summarized

Migraine drugs are critical in the management and treatment of migraines, a debilitating neurological condition characterized by intense, recurrent headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. These medications are broadly categorized into acute treatments, which alleviate symptoms during a migraine attack, and preventive treatments, which reduce the frequency and severity of attacks. Acute treatments include triptans, ergotamines, and nonsteroidal anti-inflammatory drugs (NSAIDs), while preventive treatments encompass beta-blockers, anticonvulsants, and the newer class of calcitonin gene-related peptide (CGRP) inhibitors. CGRP inhibitors, such as erenumab, fremanezumab, and galcanezumab, have revolutionized migraine prevention by targeting the CGRP pathway, which plays a crucial role in migraine pathophysiology. The availability of these targeted therapies has significantly improved the quality of life for many migraine sufferers who previously found limited relief with traditional medications.

The global market for migraine drugs has expanded rapidly, driven by the increasing prevalence of migraines and the growing awareness of the condition's impact on quality of life. According to the World Health Organization, migraines are one of the leading causes of disability worldwide, affecting an estimated one billion people. This high prevalence has underscored the need for effective migraine management strategies and spurred research and development in this field. Pharmaceutical companies are investing heavily in the development of novel migraine therapies, including next-generation CGRP inhibitors and combination therapies that offer enhanced efficacy and reduced side effects. Additionally, the introduction of digital therapeutics, which utilize mobile apps and wearable devices to monitor and manage migraines, represents a significant advancement in personalized migraine care. These digital tools enable patients to track their symptoms, triggers, and medication usage, facilitating more precise and effective treatment plans.

The growth in the migraine drugs market is driven by several factors, including technological advancements in drug development, increasing demand for personalized medicine, and the rising prevalence of chronic migraines. Technological innovations have led to the development of more effective and targeted therapies, such as CGRP inhibitors, which have transformed migraine prevention and treatment. The increasing demand for personalized medicine has also propelled the market, as patients seek treatments tailored to their specific genetic and lifestyle factors. Additionally, the rising prevalence of chronic migraines, which affect a significant portion of the global population, has created a substantial demand for effective migraine treatments. The expansion of healthcare infrastructure in emerging markets and the growing accessibility of advanced migraine therapies have further fueled market growth. Furthermore, increased awareness and education about migraines and their treatment options have empowered patients to seek medical help, thereby driving the demand for migraine drugs. These factors collectively contribute to the robust growth of the migraine drugs market, reflecting the ongoing advancements in medical research and the evolving needs of migraine sufferers worldwide.

SCOPE OF STUDY:

The report analyzes the Migraine Drugs market by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Acute Treatment, Preventive Treatment); Therapeutic Class (CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class, Other Therapeutic Class); Administration Route (Oral Administration Route, Injectable Administration Route, Other Administration Routes); Age Group (Pediatric Age Group, Adult Age Group, Geriatric Age Group)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • Allergan PLC
  • Amgen, Inc.
  • Biohaven Pharmaceutical Holding Company Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • Migraine Drugs - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 59 Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic Migraines Expands Addressable Market Opportunity
    • Advances in CGRP Inhibitors Propel Growth in Migraine Treatment
    • Increasing Demand for Personalized Medicine Spurs Adoption of Tailored Therapies
    • Innovations in Digital Therapeutics Strengthen Business Case for Migraine Management
    • Growing Awareness of Migraine Impact on Quality of Life Drives Market Expansion
    • Technological Innovations in Drug Delivery Systems Propel Growth
    • Introduction of Combination Therapies Accelerates Demand for Migraine Drugs
    • Increased Investment in Migraine Research and Development Spurs Market Innovation
    • Focus on Reducing Side Effects and Improving Efficacy Drives Adoption of New Therapies
    • Consumer Preference for Non-Pharmacological Treatments Throws the Spotlight on Alternative Therapies
    • Rising Healthcare Expenditure Sustains Growth in Migraine Drugs Market
    • Growth of Telemedicine and Remote Monitoring Expands Accessibility to Migraine Care
    • Focus on Long-Term Preventive Treatments Expands Addressable Market
    • Increasing Prevalence of Lifestyle-Related Triggers Strengthens Business Case for Migraine Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Migraine Drugs Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
    • TABLE 2: World Recent Past, Current & Future Analysis for Migraine Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 3: World Historic Review for Migraine Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 4: World 13-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for Acute Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for Acute Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for Acute Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Preventive Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Preventive Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Preventive Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for CGRP Monoclonal Antibodies Therapeutic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for CGRP Monoclonal Antibodies Therapeutic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for CGRP Monoclonal Antibodies Therapeutic Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for CGRP Small Molecule Antagonists Therapeutic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for CGRP Small Molecule Antagonists Therapeutic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for CGRP Small Molecule Antagonists Therapeutic Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Acetylcholine Inhibitors / Neurotoxins Therapeutic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Acetylcholine Inhibitors / Neurotoxins Therapeutic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Acetylcholine Inhibitors / Neurotoxins Therapeutic Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Triptans Therapeutic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Triptans Therapeutic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Triptans Therapeutic Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Ditans Therapeutic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Ditans Therapeutic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Ditans Therapeutic Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Ergot Alkaloids Therapeutic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Ergot Alkaloids Therapeutic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Ergot Alkaloids Therapeutic Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for NSAIDs Therapeutic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for NSAIDs Therapeutic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for NSAIDs Therapeutic Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Therapeutic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 33: World Historic Review for Other Therapeutic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 34: World 13-Year Perspective for Other Therapeutic Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 35: World Recent Past, Current & Future Analysis for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 36: World Historic Review for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 37: World 13-Year Perspective for Oral Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 38: World Recent Past, Current & Future Analysis for Injectable Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 39: World Historic Review for Injectable Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 40: World 13-Year Perspective for Injectable Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 41: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 42: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 43: World 13-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 44: World Recent Past, Current & Future Analysis for Pediatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 45: World Historic Review for Pediatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 46: World 13-Year Perspective for Pediatric Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 47: World Recent Past, Current & Future Analysis for Adult Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 48: World Historic Review for Adult Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 49: World 13-Year Perspective for Adult Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 50: World Recent Past, Current & Future Analysis for Geriatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 51: World Historic Review for Geriatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 52: World 13-Year Perspective for Geriatric Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 53: USA Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 54: USA Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 55: USA 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 56: USA Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 57: USA Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 58: USA 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 59: USA Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 60: USA Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 61: USA 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 62: USA Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 63: USA Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 64: USA 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 66: Canada Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 67: Canada 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 69: Canada Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 70: Canada 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 72: Canada Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 73: Canada 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 75: Canada Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 76: Canada 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • JAPAN
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 78: Japan Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 79: Japan 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 81: Japan Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 82: Japan 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 84: Japan Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 85: Japan 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 87: Japan Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 88: Japan 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • CHINA
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 89: China Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 90: China Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 91: China 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 92: China Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 93: China Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 94: China 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 95: China Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 96: China Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 97: China 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 98: China Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 99: China Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 100: China 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • EUROPE
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Migraine Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 102: Europe Historic Review for Migraine Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 103: Europe 13-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 105: Europe Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 106: Europe 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 108: Europe Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 109: Europe 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 111: Europe Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 112: Europe 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 114: Europe Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 115: Europe 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • FRANCE
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 116: France Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 117: France Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 118: France 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 119: France Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 120: France Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 121: France 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 122: France Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 123: France Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 124: France 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 125: France Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 126: France Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 127: France 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • GERMANY
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Germany Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 130: Germany 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Germany Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 133: Germany 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 134: Germany Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Germany Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 136: Germany 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 137: Germany Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Germany Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 139: Germany 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Italy Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 142: Italy 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 144: Italy Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 145: Italy 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 146: Italy Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 147: Italy Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 148: Italy 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 149: Italy Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 150: Italy Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 151: Italy 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 152: UK Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 153: UK Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 154: UK 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 155: UK Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 156: UK Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 157: UK 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 158: UK Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 159: UK Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 160: UK 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 161: UK Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 162: UK Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 163: UK 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 165: Spain Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 166: Spain 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 167: Spain Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 168: Spain Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 169: Spain 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 170: Spain Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 171: Spain Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 172: Spain 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 173: Spain Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 174: Spain Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 175: Spain 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 177: Russia Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 178: Russia 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 179: Russia Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 180: Russia Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 181: Russia 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 182: Russia Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 183: Russia Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 184: Russia 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 185: Russia Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 186: Russia Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 187: Russia 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 190: Rest of Europe 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 193: Rest of Europe 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 196: Rest of Europe 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 198: Rest of Europe Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 199: Rest of Europe 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Migraine Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 202: Asia-Pacific 13-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 205: Asia-Pacific 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 208: Asia-Pacific 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 211: Asia-Pacific 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 214: Asia-Pacific 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 216: Australia Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 217: Australia 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 218: Australia Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 219: Australia Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 220: Australia 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 221: Australia Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 222: Australia Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 223: Australia 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 224: Australia Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 225: Australia Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 226: Australia 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • INDIA
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 227: India Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 228: India Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 229: India 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 230: India Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 231: India Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 232: India 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 233: India Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 234: India Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 235: India 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 236: India Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 237: India Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 238: India 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 240: South Korea Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 241: South Korea 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 243: South Korea Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 244: South Korea 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 246: South Korea Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 247: South Korea 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 248: South Korea Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 249: South Korea Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 250: South Korea 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Rest of Asia-Pacific Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 262: Rest of Asia-Pacific 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 264: Latin America Historic Review for Migraine Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 265: Latin America 13-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 267: Latin America Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 268: Latin America 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 270: Latin America Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 271: Latin America 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 273: Latin America Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 274: Latin America 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 276: Latin America Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 277: Latin America 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 279: Argentina Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 280: Argentina 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 282: Argentina Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 283: Argentina 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 285: Argentina Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 286: Argentina 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 287: Argentina Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 288: Argentina Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 289: Argentina 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 291: Brazil Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 292: Brazil 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 294: Brazil Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 295: Brazil 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 296: Brazil Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 297: Brazil Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 298: Brazil 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 299: Brazil Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 300: Brazil Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 301: Brazil 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 303: Mexico Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 304: Mexico 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 306: Mexico Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 307: Mexico 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 308: Mexico Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 309: Mexico Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 310: Mexico 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 311: Mexico Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 312: Mexico Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 313: Mexico 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 316: Rest of Latin America 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 319: Rest of Latin America 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 321: Rest of Latin America Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 322: Rest of Latin America 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 324: Rest of Latin America Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 325: Rest of Latin America 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 327: Middle East Historic Review for Migraine Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 328: Middle East 13-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 330: Middle East Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 331: Middle East 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 333: Middle East Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 334: Middle East 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 335: Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 336: Middle East Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 337: Middle East 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 339: Middle East Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 340: Middle East 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 342: Iran Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 343: Iran 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 344: Iran Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 345: Iran Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 346: Iran 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 347: Iran Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 348: Iran Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 349: Iran 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 350: Iran Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 351: Iran Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 352: Iran 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 354: Israel Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 355: Israel 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 356: Israel Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 357: Israel Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 358: Israel 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 359: Israel Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 360: Israel Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 361: Israel 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 362: Israel Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 363: Israel Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 364: Israel 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 367: Saudi Arabia 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 370: Saudi Arabia 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 372: Saudi Arabia Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 373: Saudi Arabia 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 375: Saudi Arabia Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 376: Saudi Arabia 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 378: UAE Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 379: UAE 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 380: UAE Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 381: UAE Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 382: UAE 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 383: UAE Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 384: UAE Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 385: UAE 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 386: UAE Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 387: UAE Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 388: UAE 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 391: Rest of Middle East 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 394: Rest of Middle East 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 396: Rest of Middle East Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 397: Rest of Middle East 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 399: Rest of Middle East Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 400: Rest of Middle East 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032
  • AFRICA
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 402: Africa Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 403: Africa 13-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2020, 2026 & 2032
    • TABLE 404: Africa Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 405: Africa Historic Review for Migraine Drugs by Therapeutic Class - CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 406: Africa 13-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for CGRP Monoclonal Antibodies Therapeutic Class, CGRP Small Molecule Antagonists Therapeutic Class, Acetylcholine Inhibitors / Neurotoxins Therapeutic Class, Triptans Therapeutic Class, Ditans Therapeutic Class, Ergot Alkaloids Therapeutic Class, NSAIDs Therapeutic Class and Other Therapeutic Class for the Years 2020, 2026 & 2032
    • TABLE 407: Africa Recent Past, Current & Future Analysis for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 408: Africa Historic Review for Migraine Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 409: Africa 13-Year Perspective for Migraine Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
    • TABLE 410: Africa Recent Past, Current & Future Analysis for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 411: Africa Historic Review for Migraine Drugs by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 412: Africa 13-Year Perspective for Migraine Drugs by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2020, 2026 & 2032

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기